NASDAQ
23.50USD
0.00 (0.00%)
We have scored 14 news catalysts on Assertio Holdings, Inc. (ASRT) over the past 12 months. The biggest single-day move next to one of them came Apr 1, 2026, when ASRT closed +4.3%: “Top 2 Health Care Stocks That May Implode In April”. Coverage across the window leans negative (average ticker sentiment −0.23). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
151.9M
P/E
—
EPS
—
Beta
0.53
52W range
8.61-23.5
Day range
23.48–23.50
Open
23.48
Prev close
23.50
Volume
270.2K
Avg volume
327.5K
Dividend
0.00
IPO
1997-12-03
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Assertio Holdings, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ASRT: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Assertio Holdings, Inc. is a specialized pharmaceutical company focused on developing and commercializing therapeutic solutions across key medical domains, including neurology, hospital care, and pain and inflammation management. Among its portfolio, Assertio offers INDOCIN, available as both an oral solution and a suppository. This medication addresses conditions such as moderate to severe rheumatoid arthritis (including acute flare-ups), ankylosing spondylitis, osteoarthritis, acute painful shoulder, and gouty arthritis. The company's offerings also encompass CAMBIA, an NSAID specifically formulated to alleviate symptoms associated with migraine headaches, including nausea, light sensitivity (photophobia), and sound sensitivity (phonophobia). Zipsor, another NSAID, is indicated for managing mild to moderate acute pain. For more significant short-term pain relief, SPRIX, also an NSAID, provides analgesia comparable to opioid-level treatments for moderate to moderately severe pain. Rounding out its product line is Otrexup, a prescription methotrexate delivered via a convenient single-dose auto-injector. This therapy targets severe, active rheumatoid arthritis in adults and active polyarticular juvenile idiopathic arthritis in pediatric patients. Initially incorporated as Assertio Therapeutics, Inc. in 1995, the organization rebranded to Assertio Holdings, Inc. in May 2020 and maintains its corporate headquarters in Lake Forest, Illinois.
